Alcon Reports Strong Q4 2025 Sales Growth Amid Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy ALC?
Source: Benzinga
Alcon's stock rose by 3.03% as it reached a 20-day high, reflecting positive investor sentiment following its Q4 2025 financial results.
The company reported Q4 2025 sales of $2.7 billion, a 9% increase year-over-year, driven by innovative product launches, despite a diluted EPS of $0.78 falling short of market expectations. Alcon's strong cash flow performance, with net cash flows from operating activities reaching $2.271 billion, indicates ongoing improvements in financial management, although concerns about future profitability due to tariffs were raised.
Investors are encouraged by the sales growth and cash flow improvements, but the earnings miss may temper enthusiasm as they assess the company's ability to navigate competitive pressures in the eye care market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 74.470
Low
78.17
Averages
93.73
High
117.26
Current: 74.470
Low
78.17
Averages
93.73
High
117.26
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lensar Terminates Merger Agreement with Alcon Amid Regulatory Challenges
- Merger Agreement Termination: Lensar announced the termination of its merger agreement with Alcon due to regulatory challenges, while retaining a $10 million deposit, reflecting a cautious approach towards future transactions.
- Significant Stock Drop: Following the termination of the merger agreement, Lensar's shares plummeted 24% in after-hours trading, indicating a strong market reaction to the failed deal that could impact the company's future financing capabilities.
- Regulatory Review Delays: The transaction originally planned for March 2025 between Lensar and Alcon has been postponed due to opposition from the Federal Trade Commission, with completion now expected in the first half of 2026, increasing uncertainty around the deal.
- Market Sentiment Analysis: Despite LNSR stock dropping 34% over the past 12 months, retail investor sentiment on Stocktwits remains 'bullish', while ALC sentiment is 'neutral', suggesting ongoing confidence in Lensar's future prospects.
See More
Alcon Terminates Merger Agreement with LENSAR
- Merger Termination: Alcon has announced the termination of its merger agreement with LENSAR, believing that the acquisition would have significantly enhanced FLACS innovation and competition; however, the delay and associated costs have rendered the transaction unattractive.
- Regulatory Challenges: The delay in the transaction is closely tied to opposition from the Federal Trade Commission, highlighting significant challenges faced by the healthcare industry in mergers and acquisitions under the current regulatory environment, which may impact future M&A strategies.
- Continued Commitment: Alcon's CEO, David J. Endicott, reaffirmed the company's commitment to advancing cataract surgery through innovative technologies that improve efficiency for surgeons and outcomes for patients, indicating a long-term strategic direction in the eye care sector.
- Market Impact: The termination of this merger may have a short-term negative impact on Alcon's market performance, but it also provides an opportunity for the company to focus resources on other innovative projects, potentially enhancing its competitive position in the future.
See More
Lensar and Alcon Terminate Merger Agreement
- Merger Agreement Termination: Lensar and Alcon have agreed to terminate their planned merger due to anticipated opposition from the Federal Trade Commission, highlighting the regulatory challenges facing industry consolidation.
- Deposit Retention: Lensar will retain the $10 million deposit stipulated in the merger agreement, which somewhat alleviates the financial burden resulting from the failed transaction.
- Market Commitment: Lensar's CEO Nick Curtis expressed disappointment over the merger's outcome but reaffirmed the company's commitment to advancing cataract surgery through its ALLY Robotic Cataract Laser System, indicating confidence in market growth.
- Historical Context: Alcon had previously agreed to acquire Lensar for $14 per share last March, and the termination of this deal reflects a cautious sentiment in the medical device sector regarding mergers, potentially impacting future investor confidence.
See More
Goldman Sachs Analysts Warn of Market Risks
- Market Risk Warning: Goldman Sachs strategist Peter Oppenheimer highlights that current equity market risk premia have fallen to levels not seen since the lead-up to the 2008 financial crisis, indicating a need for caution despite improved market sentiment.
- AIG Financial Performance: American International Group (AIG) reported net premiums of $23.9 billion in 2024 and $23.8 billion in 2025, with a 48% year-over-year increase in general insurance underwriting income in Q4 2025, showcasing strong earnings growth potential.
- AIG Shareholder Returns: AIG returned $6.8 billion to shareholders over the past year, with $5.8 billion in share repurchases and $1 billion in dividends, demonstrating the company's capital management flexibility and commitment to shareholder value.
- Alcon Growth Outlook: Alcon achieved $2.7 billion in sales in Q4 2025, a 9% year-over-year increase, slightly below estimates, yet analysts remain optimistic about future growth, projecting a 27% increase in share price by 2027.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Rating changes by analysts typically attract market attention, as investors may adjust their positions based on these ratings, potentially impacting the price volatility of related stocks.
- Impact of Rating Changes: Upgrades can boost investor confidence and drive stock prices higher, while downgrades may lead to price declines, highlighting the significant role analysts play in the market.
- Access More Information: For a complete view of all analyst rating changes, including specific upgrades and downgrades, investors can visit our analyst ratings page to obtain the latest data and analysis.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: Analysts have issued upgrades and downgrades on certain stocks, with these rating changes likely to directly impact the stock price fluctuations of the affected companies, necessitating investor attention.
- Market Reaction: Rating changes often trigger immediate market reactions, as investors may adjust their positions based on analysts' recommendations, thereby affecting overall market sentiment and liquidity.
- Investment Insights: While the article does not provide specific investment advice, the changes in analysts' ratings offer crucial reference points for investors, aiding them in making more informed investment decisions.
See More
Lensar Terminates Merger Agreement with Alcon Amid Regulatory Challenges
- Merger Agreement Termination: Lensar announced the termination of its merger agreement with Alcon due to regulatory challenges, while retaining a $10 million deposit, reflecting a cautious approach towards future transactions.
- Significant Stock Drop: Following the termination of the merger agreement, Lensar's shares plummeted 24% in after-hours trading, indicating a strong market reaction to the failed deal that could impact the company's future financing capabilities.
- Regulatory Review Delays: The transaction originally planned for March 2025 between Lensar and Alcon has been postponed due to opposition from the Federal Trade Commission, with completion now expected in the first half of 2026, increasing uncertainty around the deal.
- Market Sentiment Analysis: Despite LNSR stock dropping 34% over the past 12 months, retail investor sentiment on Stocktwits remains 'bullish', while ALC sentiment is 'neutral', suggesting ongoing confidence in Lensar's future prospects.
See More
Alcon Terminates Merger Agreement with LENSAR
- Merger Termination: Alcon has announced the termination of its merger agreement with LENSAR, believing that the acquisition would have significantly enhanced FLACS innovation and competition; however, the delay and associated costs have rendered the transaction unattractive.
- Regulatory Challenges: The delay in the transaction is closely tied to opposition from the Federal Trade Commission, highlighting significant challenges faced by the healthcare industry in mergers and acquisitions under the current regulatory environment, which may impact future M&A strategies.
- Continued Commitment: Alcon's CEO, David J. Endicott, reaffirmed the company's commitment to advancing cataract surgery through innovative technologies that improve efficiency for surgeons and outcomes for patients, indicating a long-term strategic direction in the eye care sector.
- Market Impact: The termination of this merger may have a short-term negative impact on Alcon's market performance, but it also provides an opportunity for the company to focus resources on other innovative projects, potentially enhancing its competitive position in the future.
See More
Lensar and Alcon Terminate Merger Agreement
- Merger Agreement Termination: Lensar and Alcon have agreed to terminate their planned merger due to anticipated opposition from the Federal Trade Commission, highlighting the regulatory challenges facing industry consolidation.
- Deposit Retention: Lensar will retain the $10 million deposit stipulated in the merger agreement, which somewhat alleviates the financial burden resulting from the failed transaction.
- Market Commitment: Lensar's CEO Nick Curtis expressed disappointment over the merger's outcome but reaffirmed the company's commitment to advancing cataract surgery through its ALLY Robotic Cataract Laser System, indicating confidence in market growth.
- Historical Context: Alcon had previously agreed to acquire Lensar for $14 per share last March, and the termination of this deal reflects a cautious sentiment in the medical device sector regarding mergers, potentially impacting future investor confidence.
See More
Goldman Sachs Analysts Warn of Market Risks
- Market Risk Warning: Goldman Sachs strategist Peter Oppenheimer highlights that current equity market risk premia have fallen to levels not seen since the lead-up to the 2008 financial crisis, indicating a need for caution despite improved market sentiment.
- AIG Financial Performance: American International Group (AIG) reported net premiums of $23.9 billion in 2024 and $23.8 billion in 2025, with a 48% year-over-year increase in general insurance underwriting income in Q4 2025, showcasing strong earnings growth potential.
- AIG Shareholder Returns: AIG returned $6.8 billion to shareholders over the past year, with $5.8 billion in share repurchases and $1 billion in dividends, demonstrating the company's capital management flexibility and commitment to shareholder value.
- Alcon Growth Outlook: Alcon achieved $2.7 billion in sales in Q4 2025, a 9% year-over-year increase, slightly below estimates, yet analysts remain optimistic about future growth, projecting a 27% increase in share price by 2027.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Rating changes by analysts typically attract market attention, as investors may adjust their positions based on these ratings, potentially impacting the price volatility of related stocks.
- Impact of Rating Changes: Upgrades can boost investor confidence and drive stock prices higher, while downgrades may lead to price declines, highlighting the significant role analysts play in the market.
- Access More Information: For a complete view of all analyst rating changes, including specific upgrades and downgrades, investors can visit our analyst ratings page to obtain the latest data and analysis.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Upgrades and Downgrades: Analysts have issued upgrades and downgrades on certain stocks, with these rating changes likely to directly impact the stock price fluctuations of the affected companies, necessitating investor attention.
- Market Reaction: Rating changes often trigger immediate market reactions, as investors may adjust their positions based on analysts' recommendations, thereby affecting overall market sentiment and liquidity.
- Investment Insights: While the article does not provide specific investment advice, the changes in analysts' ratings offer crucial reference points for investors, aiding them in making more informed investment decisions.
See More
